Evaluation of the Architect® tacrolimus assay in kidney, liver, and heart transplant recipients
Authors:
- Caroline BarauCBCaroline Barau
- Claire GozaloCGClaire Gozalo
- 1 December 2010
- journal article
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 53 (4) , 997-1002
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Specificity of a Circulating Antibody That Interferes With a Widely Used Tacrolimus ImmunoassayTherapeutic Drug Monitoring, 2010
- Therapeutic monitoring of Tacrolimus: Aberrant results by an immunoassay with automated pretreatmentClinica Chimica Acta, 2010
- Multi-site Analytical Evaluation of the Abbott ARCHITECT Tacrolimus AssayTherapeutic Drug Monitoring, 2009
- Opportunities to Optimize Tacrolimus Therapy in Solid Organ Transplantation: Report of the European Consensus ConferenceTherapeutic Drug Monitoring, 2009
- Evaluation of 2 Immunoassays for Monitoring Low Blood Levels of TacrolimusTherapeutic Drug Monitoring, 2009
- Falsely Elevated Whole Blood Tacrolimus Concentrations due to Interference in an Affinity Column-Mediated Immunoassay Method on Xpand DimensionTherapeutic Drug Monitoring, 2009
- Falsely Increased Blood Tacrolimus Concentrations Using the ACMIA Assay Due to Circulating Endogenous Antibodies in a Liver Transplant Recipient: A Tentative Approach to Obtaining Reliable ResultsTherapeutic Drug Monitoring, 2009
- Human Anti-Mouse Antibodies Interferences in Elecsys PTH Assay After OKT3 TreatmentTransplantation, 2009
- RELATIONSHIP OF FK506 WHOLE BLOOD CONCENTRATIONS AND EFFICACY AND TOXICITY AFTER LIVER AND KIDNEY TRANSPLANTATIONTransplantation, 1996
- AN OPEN-LABEL, CONCENTRATION-RANGING TRIAL OF FK506 IN PRIMARY KIDNEY TRANSPLANTATIONTransplantation, 1996